Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE

User menu

  • Log out
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log out
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE
PreviousNext
Articles

Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection

JK Morse, SJ Wiegand, K Anderson, Y You, N Cai, J Carnahan, J Miller, PS DiStefano, CA Altar and RM Lindsay
Journal of Neuroscience 1 October 1993, 13 (10) 4146-4156; https://doi.org/10.1523/JNEUROSCI.13-10-04146.1993
JK Morse
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SJ Wiegand
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Anderson
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y You
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N Cai
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Carnahan
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Miller
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PS DiStefano
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CA Altar
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RM Lindsay
Regeneron Pharmaceuticals Inc., Tarrytown, New York 10591–6707.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, supports the survival of developing basal forebrain cholinergic neurons in vitro and is retrogradely transported by cholinergic neurons of the medial septum and diagonal band following intrahippocampal injections in vivo. To substantiate a potential role for BDNF in the maintenance of forebrain cholinergic neurons in the adult brain, we assessed the ability of BDNF to sustain the phenotype of medial septal cholinergic neurons following a unilateral transection of the fimbria. BDNF, NGF, or vehicle solutions were infused continuously in adult female rats either into the lateral ventricle (intracerebroventricularly) or directly into the septum for 2 weeks beginning at the time of the transection. In vehicle-infused animals, only 28% of the ChAT-immunoreactive neurons remained on the side ipsilateral to the lesion compared to the contralateral intact side. When infused intracerebroventricularly, both BDNF and NGF reduced the extent of the phenotypic loss, in that 44% and 68%, respectively, of the ChAT-immunopositive neurons remained on the lesioned side. Intraseptal infusion proved even more effective, in that following BDNF and NGF treatment 60% and 86%, respectively, of the normal complement of ChAT-immunopositive neurons were apparent on the side ipsilateral to the lesion. Similar results were obtained when an antibody to the low- affinity NGF receptor was used to identify the cholinergic neurons. To determine if the apparent greater efficacy of NGF compared to BDNF might be related to differences in delivery, we examined the patterns of distribution of radiolabeled BDNF and NGF injected into the lateral ventricle. 125I-BDNF showed only very little diffusion from the ventricles into the adjacent neural tissue and negligible retrograde labeling of the neurons within the basal forebrain. 125I-NGF, however, diffused readily into the brain, resulting in widespread retrograde labeling of basal forebrain neurons. A similarly limited distribution pattern was observed where BDNF was detected immunohistochemically in animals infused intracerebroventricularly (12 micrograms/d) for 2 weeks. In contrast, when delivered intraseptally, the same dose of BDNF exhibited a widespread diffusion within the surrounding neuropil and retrograde labeling of neurons in the medial septum and the vertical limb of the diagonal band. Thus, when delivered effectively, BDNF has a substantial capacity to rescue axotomized cholinergic neurons.

Back to top

In this issue

The Journal of Neuroscience: 13 (10)
Journal of Neuroscience
Vol. 13, Issue 10
1 Oct 1993
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
View Full Page PDF
Citation Tools
Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection
JK Morse, SJ Wiegand, K Anderson, Y You, N Cai, J Carnahan, J Miller, PS DiStefano, CA Altar, RM Lindsay
Journal of Neuroscience 1 October 1993, 13 (10) 4146-4156; DOI: 10.1523/JNEUROSCI.13-10-04146.1993

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection
JK Morse, SJ Wiegand, K Anderson, Y You, N Cai, J Carnahan, J Miller, PS DiStefano, CA Altar, RM Lindsay
Journal of Neuroscience 1 October 1993, 13 (10) 4146-4156; DOI: 10.1523/JNEUROSCI.13-10-04146.1993
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

  • Memory Retrieval Has a Dynamic Influence on the Maintenance Mechanisms That Are Sensitive to ζ-Inhibitory Peptide (ZIP)
  • Neurophysiological Evidence for a Cortical Contribution to the Wakefulness-Related Drive to Breathe Explaining Hypocapnia-Resistant Ventilation in Humans
  • Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase
Show more Articles
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Accessibility
(JNeurosci logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.